Fundraising Fox

Alerje

Detroit, US · Founded 2016 · 7 employees on LinkedIn · 6 known investors

Find your way into Alerje

2 people in our graph share verified history with the Alerje team — schools, employers, funds. One of them is your warm intro.

Alerje develops FAIT, a mobile app and clinical platform for food allergy oral immunotherapy (OIT), offering dose tracking, HIPAA-compliant clinic messaging, and predictive insights. It serves families managing childhood food allergies and the allergy clinics coordinating their care.

Founders & leadership

Alerje was founded in 2016 by Javier Evelyn.

JEJavier Evelyn
Javier EvelyninFounder & CEOJavier Evelyn is Founder and CEO of Alerje, which builds AI-enabled clinical software and immunotherapy tools for people with food allergies, and previously co-founded a family-owned insurance agency and worked in mobile app development for the PBM/insurer MeridianRx (Meridian Health Plan). He is a graduate of Illinois State University.

Board

PGPatti Glaza
Patti GlazainBoard directorManaging Director at ID Ventures

Investors · 6

Reported raises · per SEC filings

Form D private placements

$2M disclosed across 2 rounds · 2020–2023

$1.9MraisedAug 2023 · 19 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Javier EvelynExecutive Officer, Director
  • Patti GlazaDirector
Offering amount
$2.6M
Amount sold
$1.9M
First sale
Jul 2023
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$75KraisedMay 2020 · 2 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Javier EvelynExecutive Officer, Director
Offering amount
$1M
Amount sold
$75K
Minimum investment
$25K
Proceeds to insiders
$40K
First sale
May 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase II2023$1M
National Science FoundationPhase I2021$255.3K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Frequently asked questions

What does Alerje do?
Alerje develops FAIT, a mobile app and clinical platform for food allergy oral immunotherapy (OIT), offering dose tracking, HIPAA-compliant clinic messaging, and predictive insights. It serves families managing childhood food allergies and the allergy clinics coordinating their care.
Who founded Alerje?
Alerje was founded by Javier Evelyn in 2016.
Who are Alerje's investors?
Alerje's investors include Backstage Capital, Chloe Capital, ID Ventures, Jumpstart Nova, Michigan Rise, Seae Ventures.
How much funding has Alerje raised?
Alerje has disclosed $2M raised across 2 rounds.
Where is Alerje headquartered?
Alerje is headquartered in Detroit, US.